ATE377754T1 - Onkolytische viren zur bestimmung des phänotypus von neoplasmen - Google Patents

Onkolytische viren zur bestimmung des phänotypus von neoplasmen

Info

Publication number
ATE377754T1
ATE377754T1 AT03737795T AT03737795T ATE377754T1 AT E377754 T1 ATE377754 T1 AT E377754T1 AT 03737795 T AT03737795 T AT 03737795T AT 03737795 T AT03737795 T AT 03737795T AT E377754 T1 ATE377754 T1 AT E377754T1
Authority
AT
Austria
Prior art keywords
neoplasms
phenotype
determining
oncolytic viruses
oncolytic
Prior art date
Application number
AT03737795T
Other languages
English (en)
Inventor
Bradley Thompson
Matthew Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of ATE377754T1 publication Critical patent/ATE377754T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03737795T 2002-06-28 2003-06-25 Onkolytische viren zur bestimmung des phänotypus von neoplasmen ATE377754T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39203102P 2002-06-28 2002-06-28
US44318803P 2003-01-29 2003-01-29

Publications (1)

Publication Number Publication Date
ATE377754T1 true ATE377754T1 (de) 2007-11-15

Family

ID=30003222

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03737795T ATE377754T1 (de) 2002-06-28 2003-06-25 Onkolytische viren zur bestimmung des phänotypus von neoplasmen
AT07021569T ATE555388T1 (de) 2002-06-28 2003-06-25 Onkolytische viren zur bestimmung des phänotypus von neoplasmen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07021569T ATE555388T1 (de) 2002-06-28 2003-06-25 Onkolytische viren zur bestimmung des phänotypus von neoplasmen

Country Status (20)

Country Link
US (3) US7306902B2 (de)
EP (2) EP1520175B1 (de)
JP (1) JP2005531306A (de)
CN (1) CN1666105B (de)
AR (1) AR039768A1 (de)
AT (2) ATE377754T1 (de)
AU (2) AU2003245760B2 (de)
BR (1) BR0311983A (de)
CA (1) CA2487824C (de)
DE (1) DE60317331T2 (de)
DK (2) DK1520175T3 (de)
ES (2) ES2385845T3 (de)
HK (2) HK1069877A1 (de)
IL (2) IL165498A0 (de)
MX (1) MXPA04012414A (de)
NZ (1) NZ537116A (de)
PT (1) PT1890151E (de)
SI (1) SI1890151T1 (de)
TW (3) TWI334444B (de)
WO (1) WO2004003562A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
WO2004009763A2 (en) 2002-07-24 2004-01-29 Arizona Board Of Regents Use of vaccinia virus deleted for the e3l gene as a vaccine vector
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20070036758A1 (en) * 2003-07-08 2007-02-15 Bertram Jacobs Mutants of vaccinia virus as oncolytic agents
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US20090311664A1 (en) * 2005-12-22 2009-12-17 Yuman Fong Method for Detection of Cancer Cells Using Virus
EP1984007B1 (de) * 2006-02-13 2015-08-19 Oncolytics Biotech Inc. Verwendung von niedrigdosiertem lokaler immunsuppression zur verstärkung einer onkolytischen viralen therapie
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
US9241998B2 (en) * 2007-05-21 2016-01-26 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oncolytic RSV activity
JP5748656B2 (ja) * 2008-05-22 2015-07-15 ジェ イル ファーマシューティカル カンパニー リミテッド 過剰増殖細胞の腫瘍抑制因子に基づいた腫瘍崩壊ウイルスに対する感受性を判定する方法
MX339014B (es) * 2008-05-27 2016-05-09 Oncolytics Biotech Inc Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
JP2011520994A (ja) * 2008-05-27 2011-07-21 オンコリティクス バイオテク，インコーポレーテッド 腫瘍崩解性レオウイルス療法中の炎症性サイトカイン産生の排除
US8481297B2 (en) * 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2012106281A2 (en) 2011-01-31 2012-08-09 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
WO2014018113A1 (en) 2012-07-24 2014-01-30 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
EP2890720B1 (de) 2012-08-30 2019-07-17 The General Hospital Corporation Zusammensetzungen und verfahren zur behandlung von krebs
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
EP3082834B1 (de) * 2013-12-11 2020-03-11 The General Hospital Corporation DBA Massachusetts Von stammzellen abgegebener onkolytischer herpes-simplex-virus und verfahren zur behandlung von hirntumoren
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
CN108064282A (zh) 2014-10-14 2018-05-22 哈洛齐梅公司 腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法
CN107735103B (zh) 2015-02-25 2022-05-27 纪念斯隆-凯特琳癌症中心 使用灭活的非复制型的修饰的痘苗病毒安卡拉(mva)作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂的组合
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
CA3015818A1 (en) 2016-02-25 2017-08-31 Memorial Sloan Kettering Cancer Center Recombinant mva or mva.delta.e3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
KR20180133395A (ko) 2016-02-25 2018-12-14 메모리얼 슬로안 케터링 캔서 센터 암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스
WO2017181148A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
SG11201808783XA (en) 2016-04-15 2018-11-29 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
US10842835B2 (en) 2016-05-25 2020-11-24 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic vaccinia virus mutants and using same for cancer treatment
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CA3032120A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
AU2017335673A1 (en) * 2016-09-27 2019-04-11 Sator Therapeutics LLC Optimized oncolytic viruses and uses thereof
US20200040059A1 (en) 2016-10-20 2020-02-06 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
JP2020507349A (ja) 2017-02-09 2020-03-12 インダプタ セラピューティクス インコーポレイテッド 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法
SG11201907769XA (en) 2017-03-16 2019-09-27 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
CN110809581A (zh) 2017-03-16 2020-02-18 高山免疫科学股份有限公司 Pd-l2变体免疫调节蛋白及其用途
HRP20231382T1 (hr) 2017-03-16 2024-02-16 Alpine Immune Sciences, Inc. Pd-l1 varijanta imunomodulacijskih proteina i njihova upotreba
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
EA202090974A1 (ru) 2017-10-18 2020-08-05 Элпайн Иммьюн Сайенсиз, Инк. Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы
CA3100046A1 (en) 2018-06-04 2019-12-12 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
EP3876951A1 (de) 2018-11-06 2021-09-15 Calidi Biotherapeutics, Inc. Verbesserte systeme für zellvermittelte onkolytische virustherapie
KR20210123289A (ko) 2018-11-21 2021-10-13 인답타 세라뷰틱스 인코포레이티드 자연 살해 세포 서브세트의 증식을 위한 방법 및 관련 조성물 및 방법
KR20210135987A (ko) 2018-11-30 2021-11-16 알파인 이뮨 사이언시즈, 인코포레이티드 Cd86 변이체 면역조절 단백질 및 그의 용도
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
JP2022524951A (ja) 2019-02-27 2022-05-11 アクティム・セラピューティクス・インコーポレイテッド 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
JP2023523429A (ja) 2020-04-22 2023-06-05 インダプタ セラピューティクス インコーポレイテッド ナチュラルキラー（ｎｋ）細胞組成物およびそれを生成させるための方法
WO2022147480A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma, Inc. Oncolytic virus encoding sialidase and multispecific immune cell engager

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5670330A (en) * 1992-09-29 1997-09-23 Mcgill University Anti-tumor agent assay using PKR
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
WO1994018992A1 (en) 1993-02-16 1994-09-01 Onyx Pharmaceuticals Cytopathic viruses for therapy and prophylaxis of neoplasia
DK0696326T5 (da) 1993-04-30 2003-07-14 Wellstat Biologics Corp Anvendelse af NDV til fremstilling af et medikament til behandling af cancer
CA2178902A1 (en) * 1993-12-14 1995-06-22 Drew Pardoll Controlled release of pharmaceutically active substances for immunotherapy
WO1995032300A1 (en) * 1994-05-23 1995-11-30 University Of Medicine & Dentistry Of New Jersey Selective biological destruction of tumor cells
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5840502A (en) * 1994-08-31 1998-11-24 Activated Cell Therapy, Inc. Methods for enriching specific cell-types by density gradient centrifugation
US6777177B1 (en) * 1997-10-10 2004-08-17 Vanderbilt University Mammalian genes involved in viral infection and tumor suppression
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
CA2508238C (en) 1997-08-13 2008-01-15 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
EP1905304A3 (de) * 1997-10-09 2008-08-13 Wellstat Biologics Corporation Behandlung von Neoplasmen mit Viren
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US6475481B2 (en) * 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
AU3001799A (en) 1998-03-12 1999-09-27 Trustees Of The University Of Pennsylvania, The Producer cells for replication selective viruses in the treatment of malignancy
ATE318176T1 (de) * 1998-08-31 2006-03-15 Julian L Ambrus Verfahren zur entfernung von hiv und anderen viren aus blut
NZ550861A (en) 1999-04-15 2009-03-31 Wellstat Biologics Corp Treatment of neoplasms with viruses
DE19934788B4 (de) * 1999-07-27 2004-05-27 T-Mobile Deutschland Gmbh Verfahren zur automatischen Anpassung von Daten an die Fähigkeiten einer Nutzer-Software
CA2386920C (en) 1999-09-17 2012-01-24 Pro-Virus, Inc. Oncolytic virus
CA2388807C (en) * 1999-11-12 2013-08-06 Matthew C. Coffey Viruses for the treatment of cellular proliferative disorders
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AR028040A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
AR028039A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
WO2002000233A2 (en) * 2000-06-26 2002-01-03 Wellstat Biologics Corporation Purging of cells using viruses
WO2002004596A2 (en) 2000-07-07 2002-01-17 President And Fellows Of Harvard College Diagnosing and treating cancer cells using mutant viruses
WO2002039117A1 (en) 2000-11-09 2002-05-16 Oncolytics Biotech, Inc. Methods for the treatment of cellular proliferative disorders
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways

Also Published As

Publication number Publication date
AU2003245760A1 (en) 2004-01-19
HK1112509A1 (en) 2008-09-05
IL220139A0 (en) 2012-07-31
CN1666105B (zh) 2015-11-25
ES2292981T3 (es) 2008-03-16
AU2003245760B2 (en) 2008-07-03
TWI402345B (zh) 2013-07-21
WO2004003562A2 (en) 2004-01-08
SI1890151T1 (sl) 2012-08-31
EP1890151B1 (de) 2012-04-25
HK1069877A1 (en) 2005-06-03
US20080014577A1 (en) 2008-01-17
TWI334444B (en) 2010-12-11
US8222036B2 (en) 2012-07-17
NZ537116A (en) 2008-04-30
ES2385845T3 (es) 2012-08-01
CA2487824A1 (en) 2004-01-08
ATE555388T1 (de) 2012-05-15
AU2008207579B2 (en) 2011-10-20
EP1520175A2 (de) 2005-04-06
DK1890151T3 (da) 2012-06-18
EP1890151A1 (de) 2008-02-20
TW201005097A (en) 2010-02-01
CN1666105A (zh) 2005-09-07
DE60317331D1 (de) 2007-12-20
PT1890151E (pt) 2012-05-25
IL220139A (en) 2013-03-24
TW200401032A (en) 2004-01-16
DE60317331T2 (de) 2008-08-21
CA2487824C (en) 2013-08-20
AR039768A1 (es) 2005-03-09
EP1520175B1 (de) 2007-11-07
IL165498A0 (en) 2006-01-15
MXPA04012414A (es) 2005-04-19
TW200940709A (en) 2009-10-01
DK1520175T3 (da) 2008-02-11
TWI327167B (en) 2010-07-11
US20100105122A1 (en) 2010-04-29
BR0311983A (pt) 2005-04-26
US7306902B2 (en) 2007-12-11
US20040029112A1 (en) 2004-02-12
AU2008207579A1 (en) 2008-09-18
JP2005531306A (ja) 2005-10-20
WO2004003562A3 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
ATE377754T1 (de) Onkolytische viren zur bestimmung des phänotypus von neoplasmen
DK1501921T3 (da) Forbedrede virusrensningsmetoder
NO2012018I2 (no) Canakinumab eller direkte ekvivalenter derav
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
ATE357440T1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
EP1723238A4 (de) Modifizierte onkolytische viren
DE60126814D1 (de) Inhalation von stickoxid
DE60308203D1 (de) Gerät zur bestimmung des stimulationschwellwertes
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
SE0202107L (sv) Surface modified stainless steel
DE50311465D1 (de) Heisssiegelfähiges Filtermaterial
DE50206735D1 (de) Küchenmaschine zum Zubereiten von Lebensmitteln
DE60237639D1 (de) Methode zur bestimmung der biologischen aktivität von difibrotid
DE60142754D1 (de) Electrophoretische Kasette zur Detektion von Biopolymeren
DE602004026773D1 (de) Verfahrensherstellung von ethern
DE602004002601D1 (de) Erkennung von Multiplexern und Austausch von Parametern
DE10290563D2 (de) Mittel zur Hemmung von Tumorzellen
DE60200713D1 (de) Zusammensetzung enthaltend getrocknetes Vollei zur Behandlung von Hepatitis
ATE519860T1 (de) Verwendung von ribozymen zur detektion ebenfalls vorhandener agenzien
DE50302846D1 (de) Gelenkige aufhängung
NO20015325D0 (no) Defekt-deteksjon
DE60200296D1 (de) Gerät zur Detektion von Vorsatzlöchern
ATE395937T1 (de) Zur erhöhung der konzentration von radioaktivem biotin bei der pretargeted radioimmuntherapie wirksame avidindimere
DE50306263D1 (de) Detektion von toxischen algen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1520175

Country of ref document: EP

REN Ceased due to non-payment of the annual fee